[
  {
    "name": "OSU-24160 (IMGN151)",
    "criteria": {
      "allowedDiseaseSettings": [
        "recurrent",
        "metastatic"
      ],
      "allowedHistologies": [
        "serous",
        "endometrioid"
      ],
      "requiresPriorChemo": true,
      "maxPriorLines": 3,
      "requiresMeasurableDisease": true,
      "excludedPriorTopo": true,
      "requiresFRa": true,
      "conditionalRequirements": [
        {
          "condition": {
            "priorIO": "no"
          },
          "excludes": true
        }
      ]
    }
  },
  {
    "name": "OSU-24149 (SGN-MesoC2)",
    "criteria": {
      "allowedDiseaseSettings": [
        "recurrent",
        "metastatic"
      ],
      "allowedHistologies": [
        "serous",
        "endometrioid"
      ],
      "requiresPriorChemo": true,
      "maxPriorLines": 3,
      "requiresMesothelin": true,
      "excludedPriorTopo": true
    }
  },
  {
    "name": "OSU-24298 (ZW191 - Zymeworks)",
    "criteria": {
      "allowedDiseaseSettings": [
        "recurrent",
        "metastatic"
      ],
      "allowedHistologies": [
        "serous",
        "endometrioid"
      ],
      "requiresPriorChemo": true,
      "maxPriorLines": 5,
      "requiresFRa": true,
      "excludedPriorTopo": true,
      "conditionalRequirements": [
        {
          "condition": {
            "priorIO": "no"
          },
          "excludes": true
        }
      ]
    }
  },
  {
    "name": "OSU-24206 (POL\u03b8 - Novobiocin)",
    "criteria": {
      "allowedDiseaseSettings": [
        "recurrent",
        "metastatic"
      ],
      "allowedHistologies": [
        "serous",
        "endometrioid"
      ],
      "requiresPriorChemo": true,
      "maxPriorLines": "unlimited",
      "requiresMeasurableDisease": true,
      "excludedPriorTopo": true
    }
  }
]
[
  {
    "trial_id": "NRG-GY025",
    "title": "Nivolumab \u00b1 Ipilimumab",
    "eligible_if": {
      "diagnosis": "Endometrial cancer",
      "stage": [
        "Recurrent",
        "Metastatic"
      ],
      "prior_chemotherapy_lines": [
        0,
        1,
        2
      ],
      "ecog": [
        0,
        1
      ]
    }
  },
  {
    "trial_id": "NRG-GY028",
    "title": "Megace \u00b1 Ipatasertib",
    "eligible_if": {
      "diagnosis": "Endometrial cancer",
      "histology": "High-grade endometrioid or carcinosarcoma",
      "measurable_disease": true,
      "prior_chemotherapy_lines": "unlimited",
      "ecog": [
        0,
        1,
        2
      ]
    }
  },
  {
    "trial_id": "OSU-23415",
    "title": "BGB-43395 CDK4 inhibitor",
    "eligible_if": {
      "diagnosis": "Endometrial cancer",
      "stage": [
        "Recurrent",
        "Metastatic"
      ],
      "measurable_disease": true,
      "prior_chemotherapy": true,
      "ecog": [
        0,
        1
      ]
    }
  },
  {
    "trial_id": "OSU-24125",
    "title": "LOXO-783 (FR\u03b1 ADC)",
    "eligible_if": {
      "diagnosis": "Endometrial cancer",
      "stage": [
        "Recurrent",
        "Metastatic"
      ],
      "measurable_disease": true,
      "prior_chemotherapy": true,
      "ecog": [
        0,
        1
      ]
    },
    "excluded": [
      "prior_FRalpha_exatecan"
    ]
  },
  {
    "trial_id": "OSU-24298",
    "title": "Zymeworks ADC (FR\u03b1)",
    "eligible_if": {
      "diagnosis": "Endometrial cancer",
      "histology": [
        "Serous",
        "Endometrioid"
      ],
      "stage": [
        "Recurrent",
        "Metastatic"
      ],
      "prior_chemotherapy": true,
      "ecog": [
        0,
        1
      ]
    }
  },
  {
    "trial_id": "NRG-GY026",
    "title": "Trastuzumab deruxtecan (HER2 2+ or 3+)",
    "eligible_if": {
      "diagnosis": "Endometrial cancer",
      "stage": "Newly diagnosed",
      "prior_chemotherapy": false,
      "her2_status": [
        "IHC 2+",
        "IHC 3+"
      ],
      "ecog": [
        0,
        1
      ]
    }
  },
  {
    "trial_id": "NRG-GY032",
    "title": "Belantamab mafodotin + dostarlimab",
    "eligible_if": {
      "diagnosis": "Endometrial cancer",
      "stage": "Newly diagnosed",
      "prior_chemotherapy": false,
      "ecog": [
        0,
        1
      ]
    }
  },
  {
    "trial_id": "OSU-21039",
    "title": "Nivolumab in dMMR patients with autoimmune disorders",
    "eligible_if": {
      "diagnosis": "Endometrial cancer",
      "mmr_status": "dMMR",
      "autoimmune_disease": true,
      "ecog": [
        0,
        1,
        2
      ]
    }
  },
  {
    "trial_id": "OSU-23193",
    "title": "ACR-368",
    "eligible_if": {
      "diagnosis": "Endometrial cancer",
      "histology": [
        "Grade 3 endometrioid",
        "Serous",
        "Clear cell",
        "Carcinosarcoma"
      ],
      "prior_chemotherapy_lines": [
        0,
        1,
        2,
        3,
        4
      ],
      "measurable_disease": true,
      "prior_immunotherapy": true,
      "ecog": [
        0,
        1
      ]
    }
  },
  {
    "trial_id": "OSU-23428",
    "title": "MK2870 TROP2 ADC + Pembrolizumab",
    "eligible_if": {
      "diagnosis": "Endometrial cancer",
      "measurable_disease": "either",
      "prior_immunotherapy": true,
      "ecog": [
        0,
        1
      ],
      "prior_therapy_lines": {
        "max": 3
      }
    },
    "excluded": [
      "prior_exatecan"
    ]
  },
  {
    "trial_id": "OSU-24149",
    "title": "SGN-MesoC2 (mesothelin)",
    "eligible_if": {
      "diagnosis": "Endometrial cancer",
      "measurable_disease": true,
      "mesothelin_expression": "positive",
      "ecog": [
        0,
        1
      ]
    }
  },
  {
    "trial_id": "OSU-24160",
    "title": "IMGN151",
    "eligible_if": {
      "diagnosis": "Endometrial cancer",
      "measurable_disease": true,
      "fralpha_expression": "moderate to high",
      "prior_chemotherapy_lines": [
        0,
        1,
        2,
        3
      ],
      "ecog": [
        0,
        1
      ]
    },
    "excluded": [
      "prior_FRalpha_exatecan"
    ]
  },
  {
    "trial_id": "OSU-24185",
    "title": "B7H4 + Tislelizumab",
    "eligible_if": {
      "diagnosis": "Endometrial cancer",
      "measurable_disease": true,
      "b7h4_expression": "positive",
      "ecog": [
        0,
        1
      ]
    }
  },
  {
    "trial_id": "OSU-24206",
    "title": "POL\u03b8 inhibitor (Novobiocin)",
    "eligible_if": {
      "diagnosis": "Endometrial cancer",
      "measurable_disease": true,
      "genetic_mutations": [
        "BRCA",
        "PALB2",
        "RAD51C",
        "RAD51D",
        "ATRX",
        "PPP2R1a",
        "ATM"
      ],
      "prior_chemotherapy": true,
      "ecog": [
        0,
        1
      ]
    }
  },
  {
    "trial_id": "OSU-25049",
    "title": "SGR-3515-101 (Wee1 inhibitor)",
    "eligible_if": {
      "diagnosis": "Endometrial cancer",
      "histology": "Uterine serous carcinoma",
      "measurable_disease": true,
      "ecog": [
        0,
        1
      ]
    }
  },
  {
    "trial_id": "EAY191-N4",
    "title": "RAS/RAF Pathway Inhibitor (EAY191-N4)",
    "eligible_if": {
      "diagnosis": "Endometrial cancer",
      "measurable_disease": true,
      "ras_raf_alteration": true,
      "prior_chemotherapy": true,
      "ecog": [
        0,
        1
      ]
    },
    "excluded": [
      "untreated_or_unstable_brain_mets",
      "prior_mek_inhibitor"
    ]
  },
  {
    "trial_id": "OSU-24119",
    "title": "XmAb541 (CLDN6 ADC) Trial \u2013 Dose Escalation (Part 1)",
    "eligible_if": {
      "diagnosis": "Endometrial cancer",
      "measurable_disease": "either",
      "ecog": [
        0,
        1
      ]
    },
    "excluded": [
      "prior_cldn6_targeted_therapy"
    ],
    "notes": "CLDN6 expression not required for Part 1 dose escalation."
      }
]
